Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Rating Raised to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen upgraded DMRA from “Sell” to “Hold.” Overall analyst sentiment remains “Buy,” with an average price target of $46.38, though recommendations range from strong buy to sell.
• Damora reported a quarterly loss of $0.40 per share, narrower than analysts’ estimated loss of $0.52; analysts expect a full-year loss of $2.09 per share.
• CEO Jennifer Jarrett bought 12,500 shares at an average price of $20.23, increasing her ownership by 2.5%.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Sunday, Wall Street Zen reports.

A number of other research firms have also recently commented on DMRA. HC Wainwright reissued a "buy" rating and issued a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Wedbush reaffirmed an "outperform" rating and set a $40.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, September 29th. TD Cowen raised shares of Damora Therapeutics, Inc. Common Stock to a "strong-buy" rating in a report on Monday, August 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Finally, Jefferies Financial Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They issued a "buy" rating and a $50.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Damora Therapeutics, Inc. Common Stock presently has an average rating of "Buy" and an average target price of $46.38.

Damora Therapeutics, Inc. Common Stock Price Performance

NASDAQ:DMRA opened at $23.70 on Friday. The company has a market cap of $1.47 billion, a PE ratio of -7.03 and a beta of 1.52. The firm's 50 day simple moving average is $22.72 and its 200 day simple moving average is $25.70. Damora Therapeutics, Inc. Common Stock has a one year low of $4.95 and a one year high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.12. Equities research analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.09 EPS for the current year.

Insider Activity

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett acquired 12,500 shares of the business's stock in a transaction dated Friday, September 25th. The stock was bought at an average price of $20.23 per share, with a total value of $252,875.00. Following the purchase, the chief executive officer owned 512,500 shares of the company's stock, valued at approximately $10,367,875. This trade represents a 2.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.40% of the company's stock.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $303,000. Arizona State Retirement System bought a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $260,000. Seven Fleet Capital Management LP bought a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $7,398,000. Finally, Braidwell LP bought a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $42,146,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Damora Therapeutics, Inc. Common Stock

Here are the key news stories impacting Damora Therapeutics, Inc. Common Stock this week:

• Positive Sentiment: Guggenheim initiated coverage with a Buy rating and a $59 price target, signaling substantial potential upside in the analyst’s view. TickerReport article
• Positive Sentiment: HC Wainwright maintained its Buy rating and $45 target despite lowering estimates. These bullish recommendations may support investor confidence. MarketBeat coverage
• Negative Sentiment: HC Wainwright reduced its projected EPS across Q4 2026 and all four quarters of 2027, and lowered its full-year estimates to losses of $1.73 per share for 2026 and $1.70 for 2027. The revisions suggest higher expected losses than previously forecast and could pressure the stock. MarketBeat coverage

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.